Incyte Corp

Затворен

СекторЗдравеопазване

124.26 -2.06

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

123.7

Максимум

127.94

Ключови измерители

By Trading Economics

Приходи

282M

586M

Продажби

401M

1.7B

P/E

Средно за сектора

15.899

55.725

EPS

2.8

Марж на печалбата

34.982

Служители

2,844

EBITDA

384M

752M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+3.04% upside

Дивиденти

By Acuity

Следващи печалби

27.10.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.5B

25B

Предишно отваряне

126.32

Предишно затваряне

124.26

Настроения в новините

By Acuity

30%

70%

62 / 339 Класиране в Healthcare

Incyte Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.09.2026 г., 20:07 ч. UTC

Social Media

Incyte Corp shares are declining, despite social media highlighting its strength in the biotechnology sector, reflecting a cumulative decline since Tuesday's close.

22.09.2026 г., 23:45 ч. UTC

Incyte Corp is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

21.09.2026 г., 20:06 ч. UTC

News

Incyte Corp's shares are declining despite announcing an expanded partnership with Specialised Therapeutics to commercialize ruxolitinib cream in Australia.

18.09.2026 г., 22:51 ч. UTC

Incyte Corp is trading modestly higher in after-market hours, reflecting broader market trends amid mixed equity performance and rising treasury yields.

17.09.2026 г., 23:26 ч. UTC

News

Incyte Corp's stock is trading higher in after-market hours as investors await an FDA decision on zilurgisertib, with a target date of September 26.

16.09.2026 г., 23:06 ч. UTC

Incyte Corp is trading lower in after-market hours, marking its lowest point since the market closed and remaining below its 20-day moving average.

15.09.2026 г., 23:06 ч. UTC

Incyte Corp shares are trading lower in after-market hours, reflecting broader market fluctuations and remaining below the 20-day moving average.

14.09.2026 г., 20:08 ч. UTC

Incyte Corp's shares are higher amid overall market gains, despite earlier volatility. Broader market concerns include rising crude oil prices and inflation.

11.09.2026 г., 22:01 ч. UTC

Incyte Corp shares are higher in after-market trading, despite a decline in consumer sentiment reflected by the Michigan Consumer Sentiment Index.

10.09.2026 г., 19:36 ч. UTC

Event
News

Incyte's MINJUVI receives funding in Ontario for lymphoma treatment. Shares are lower despite this development, currently trading below their 20-day moving average.

9.09.2026 г., 19:07 ч. UTC

Event
Social Media

Incyte Corp gains amid positive sentiment for its upcoming PDUFA date for Zilurgisertib, scheduled for September 26, despite earlier session volatility.

8.09.2026 г., 20:02 ч. UTC

News

Incyte Corp shares are lower today, driven by a downturn in the Biotechnology sub-sector. Analysts maintain a consensus "Moderate Buy" rating on the stock.

4.09.2026 г., 23:55 ч. UTC

Incyte Corp shares are higher in after-market hours, reaching an early peak before settling back. No specific news was identified to explain the movement.

3.09.2026 г., 19:16 ч. UTC

Incyte Corp shares are lower amid broader market declines influenced by rising jobless claims. The stock remains above its 20-day moving average.

2.09.2026 г., 23:16 ч. UTC

Incyte Corp shares are trading higher in after-market hours, amid a weaker-than-expected ADP payrolls report that may influence Federal Reserve interest rate decisions.

1.09.2026 г., 22:06 ч. UTC

Incyte Corp shares are higher in after-market hours, though no specific news explains the movement. Broader market pressures persist from rising bond yields.

31.08.2026 г., 20:04 ч. UTC

News

Incyte Corp shares are lower amid broader market weakness following comments from Warsh at the Jackson Hole Economic Symposium on inflation and monetary policy.

28.08.2026 г., 23:21 ч. UTC

News

Incyte Corp shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down amid rising Treasury yields and mixed ESMO data sentiment.

27.08.2026 г., 20:07 ч. UTC

News

Incyte Corp shares are lower today, reflecting broader market declines. Analysts from TD Cowen upgraded the stock to a strong buy amid ongoing positive sentiment.

26.08.2026 г., 19:36 ч. UTC

Incyte Corp shares are lower during Wednesday's session, having reached a session low earlier. No specific news was identified to explain the price movement.

25.08.2026 г., 23:21 ч. UTC

Incyte Corp. shares are trading roughly flat in after-market hours. Market sentiment is influenced by a decline in crude oil prices and easing treasury yields.

24.08.2026 г., 23:01 ч. UTC

Incyte Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

21.08.2026 г., 19:46 ч. UTC

News

Incyte Corp's stock is higher today, supported by President Pablo J. Cagnoni's recent sale of 10,801 shares at $125.56. The stock remains near its one-month high.

20.08.2026 г., 23:41 ч. UTC

Incyte Corp shares are higher in after-market trading, recovering from a slight dip and positioned above the 20-day moving average. No specific news was identified.

19.08.2026 г., 23:01 ч. UTC

Incyte Corp shares declined in after-hours trading, pulling back from earlier gains. The stock remains above its 20-day moving average and near a one-month high.

17.08.2026 г., 20:06 ч. UTC

News

Piper Sandler raised Incyte Corp's price target to $130 from $110, contributing to the stock's upward movement after four days of declines.

14.08.2026 г., 19:36 ч. UTC

Incyte Corp shares are lower, continuing a recent decline amid concerns over July retail sales, which fell 0.6% against expectations for growth.

13.08.2026 г., 23:26 ч. UTC

Incyte Corp shares are lower in after-market hours, despite broader market gains from reduced Federal Reserve rate hike expectations. No specific news was identified.

10.08.2026 г., 19:36 ч. UTC

Incyte Corp shares are higher today, maintaining an upward trend since Friday. The stock remains above its 20-day moving average, reflecting solid performance.

6.08.2026 г., 19:44 ч. UTC

Incyte Corp shares are lower amid broader biotechnology sector declines. The stock is trading near the lower end of its one-month range.

Сравнение с други в отрасъла

Ценова промяна

Incyte Corp Прогноза

Ценова цел

By TipRanks

3.04% нагоре

12-месечна прогноза

Среден 130.789 USD  3.04%

Висок 155 USD

Нисък 104 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Incyte Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

21 ratings

11

Купи

10

Задържане

0

Продай

Настроение

By Acuity

62 / 339 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation